Abstract
Early identification for heart failure (HF) may be useful for disease modifying treatment in order to reduce heart disease progression or even to reverse it. In our previous studies, we have revealed a group of heat shock proteins (HSPs) which might be related to neonatal rat cardiomyocyte hypertrophy by proteomic approach. Here, we confirm that HSPs, including HSP27 and HSP70, altered in the early stage of cardiac remodeling in vivo animal model. Furthermore, plasma concentrations of those HSPs and their potential screening value were evaluated at different stages in 222 patient subjects. Plasma HSP27, HSP70 and HSP90 were measured using enzyme-linked immunosorbent assay. Results indicate that HSP70 was positively correlated to the severity (progression) of HF (r = 0.456, p<0.001). The area under the rate of change (ROC) curve was 0.601 (p = 0.017) in patients with stage B HF and 0.835 (p<0.001) in those with stage C HF. However, HSP27 and HSP90 did not display significant changes in any stage of HF in this study. Taken together, plasma concentrations of HSP70 elevated with the progression of HF and might act as a potential screening biomarker for early diagnosis of HF.
Highlights
Cardiovascular diseases (CVDs) are major causes of mortality in the world
As for the cardiac function, we observed that the mice subjected to ISO showed an increase in fractional shortening percentage (FS%) compared with sham group at 3 days (41.9561.67% vs. 28.9961.26%), 7 days (40.4661.19% vs. 28.4060.74%) and 14 days (39.0461.67% vs. 29.5560.75%), but a decline in FS at 84 days (21.8360.66% vs. 28.5961.33%) after ISO administration (Figure 1B), suggesting that heart failure occurred in this stage after infusion of ISO for 84 days
The results showed that HSP27 and HSP70 time-dependently increased with cardiac hypertrophy but HSP90 did not changeat any stage (Figure 3)
Summary
As a final stage of CVDs, heart failure (HF) becomes more prevalent year by year. It is very important for the early warning, early diagnosis and treatment of heart failure. Among patients without signs or symptoms of HF, those at high risk of HF were defined as stage A, and those who had structural heart disease were designated as stage B. Stage C included patients with current or past symptoms of HF, and stage D designated patients with truly refractory HF. Due to the lack of a screening strategy for detection, when diagnosed HF in hospital, the patients had always developed into the stage C or even stage D. An adequate screening test for early detection of stage B patients might greatly improve HF survival
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
